20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cytek Biosciences Inc (CTKB) operates in the MEDICAL DEVICES industry and is headquartered in Fremont, United States with about 682 employees. Its market capitalization is roughly $775 million. In the fiscal year ended 2025-12-31, CTKB reported $201M in revenue and ($67M) in net income.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.
Interactive charts & full statements → Open the CTKB valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $207M | $201M | $200M | $193M | $164M | $128M | $93M | $58M |
| Gross Profit | $110M | $104M | $111M | $109M | $101M | $79M | $52M | $29M |
| Gross Margin % | 53.2% | 51.8% | 55.4% | 56.7% | 61.6% | 61.9% | 55.7% | 49.5% |
| Operating Income (EBIT) | ($45M) | ($40M) | ($21M) | ($28M) | ($2M) | $9M | $14M | ($17M) |
| Operating Margin % | -21.6% | -20.0% | -10.2% | -14.4% | -1.1% | 7.2% | 14.7% | -29.8% |
| Net Income | ($81M) | ($67M) | ($6M) | ($12M) | $3M | $3M | $19M | ($17M) |
| Net Margin % | -39.0% | -33.0% | -3.0% | -6.3% | 1.6% | 2.4% | 20.9% | -29.1% |
| EBITDA | ($27M) | ($17M) | $5M | ($4M) | $9M | $9M | $15M | ($16M) |
| Earnings Per Share (EPS) | $-0.63 | $-0.52 | $-0.05 | $-0.09 | $0.02 | $0.02 | $0.15 | $-0.13 |
| Shares Outstanding (M) | 129M | 128M | 131M | 135M | 139M | 134M | 133M | 133M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $48M | $44M | $62M | $52M | $46M | $41M | $57M | $52M |
| Gross Profit | $28M | $21M | $33M | $28M | $24M | $20M | $34M | $29M |
| Gross Margin % | 58.9% | 48.2% | 52.9% | 52.7% | 52.3% | 48.6% | 58.6% | 56.3% |
| Operating Income (EBIT) | ($11M) | ($18M) | ($6M) | ($9M) | ($11M) | ($15M) | $3M | ($4M) |
| Operating Margin % | -23.7% | -41.8% | -9.0% | -17.6% | -23.3% | -36.1% | 5.2% | -8.2% |
| Net Income | ($12M) | ($19M) | ($44M) | ($5M) | ($6M) | ($11M) | $10M | $1M |
| Net Margin % | -25.3% | -42.8% | -70.9% | -10.5% | -12.2% | -27.5% | 16.8% | 1.8% |
| EBITDA | ($8M) | ($14M) | $0M | ($4M) | ($3M) | ($8M) | ($2M) | $3M |
| Earnings Per Share (EPS) | $-0.09 | $-0.15 | $-0.34 | $-0.04 | $-0.04 | $-0.09 | $0.07 | $0.01 |
| Shares Outstanding (M) | 129M | 129M | 128M | 128M | 127M | 128M | 129M | 133M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($6M) | ($5M) | $25M | $5M | ($12M) | $5M | $15M | ($14M) |
| Capital Expenditures (CapEx) | $6M | $4M | $4M | $5M | $10M | $4M | $2M | $1M |
| Free Cash Flow (FCF) | ($12M) | ($9M) | $22M | $0M | ($22M) | $0M | $14M | ($15M) |
| FCF Margin % | -5.8% | -4.3% | 10.9% | 0.2% | -13.5% | 0.2% | 14.7% | -25.4% |
| Dividends Paid | — | — | — | $1M | $0M | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $1M | ($3M) | ($1M) | ($4M) | $0M | $0M | $2M | $13M |
| Capital Expenditures (CapEx) | $2M | $2M | $1M | $1M | $2M | $1M | $1M | $1M |
| Free Cash Flow (FCF) | ($1M) | ($5M) | ($2M) | ($5M) | ($1M) | ($1M) | $1M | $12M |
| FCF Margin % | -1.8% | -11.1% | -2.9% | -8.7% | -3.2% | -2.4% | 1.9% | 24.1% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $447M | $462M | $500M | $494M | $519M | $463M | $220M | $70M |
| Cash & Cash Equivalents | $74M | $91M | $99M | $167M | $297M | $365M | $165M | $30M |
| Total Liabilities | $125M | $120M | $104M | $101M | $94M | $58M | $236M | $112M |
| Total Debt (Short + Long-Term) | $13M | $10M | $9M | $5M | $6M | $15M | $3M | $7M |
| Total Shareholders' Equity | $322M | $342M | $396M | $393M | $425M | $405M | ($16M) | ($42M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CTKB viewer.
About TickerBase · Data methodology & sources · Privacy · Terms